
Spectra WAVE, Inc. is a medical device company focused on improving PCI outcomes through advanced imaging technology. Their flagship product, the Hyper Vue Imaging System, combines Deep OCT™ and NIRS to provide high-resolution images for coronary artery assessment, enabling better clinical decision-making. The system is designed for efficient workflows in cath labs, offering features like AI-powered insights and a low-profile imaging catheter. With a commitment to enhancing patient outcomes, Spectra WAVE is positioned to make significant impacts in the cardiovascular imaging market.

Spectra WAVE, Inc. is a medical device company focused on improving PCI outcomes through advanced imaging technology. Their flagship product, the Hyper Vue Imaging System, combines Deep OCT™ and NIRS to provide high-resolution images for coronary artery assessment, enabling better clinical decision-making. The system is designed for efficient workflows in cath labs, offering features like AI-powered insights and a low-profile imaging catheter. With a commitment to enhancing patient outcomes, Spectra WAVE is positioned to make significant impacts in the cardiovascular imaging market.
What they do: Medical device company developing intravascular optical imaging and physiology systems for PCI (HyperVue, DeepOCT+NIRS, X1-FFR)
Founded: 2017
Headquarters: Waltham / Bedford, Massachusetts, USA
Recent funding: Series B announced Sep 11, 2024
Notable investors: Johnson & Johnson Innovation (JJDC), Deerfield Management, Nova Ventures
Coronary artery disease diagnosis and guidance of percutaneous coronary intervention (PCI).
2017
Biotechnology
13,200,000
Company announced a $13.2M Series A-2 financing on Feb 3, 2021.
Series B announced Sep 11, 2024.
“Johnson & Johnson Innovation (JJDC), Deerfield Management, Nova Ventures, Heartwork Capital, Lumira Ventures, S3 Ventures, SV Health Investors”